News - Novartis, Respiratory and Pulmonary

Filter

Popular Filters

1 to 25 of 36 results

Novartis’ Onbrez shows non-inferiority to GSK’s Seretide in COPD

Novartis’ Onbrez shows non-inferiority to GSK’s Seretide in COPD

28-04-2014

Swiss drug major Novartis has announced encouraging top-line results from its Phase IV INSTEAD switch…

EuropeHealth Medical PharmaMedicineModerate COPDNovartisOnbrezPharmaceuticalPulmonologyResearchRespiratory and PulmonaryRespiratory therapySeretide

Minor added benefit of Novartis’ Ultibro/Xoterna Breezhaler in COPD, says IQWiG

Minor added benefit of Novartis’ Ultibro/Xoterna Breezhaler in COPD, says IQWiG

19-02-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

GermanyNorthern EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryUltibro BreezhalerXoterna Breezhaler

EMA/CHMP gives Novartis positive opinion for Xolair; negative opinion on RLX030 to be appealed

EMA/CHMP gives Novartis positive opinion for Xolair; negative opinion on RLX030 to be appealed

24-01-2014

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has given…

Cardio-vascularEuropeNovartisPharmaceuticalRegulationRespiratory and PulmonaryXolair

Vectura posts flat sales and increased loss for first-half 2013

19-11-2013

UK-based developer of inhaled therapies Vectura Group has announced its unaudited interim results for…

FinancialNovartisPharmaceuticalRespiratory and PulmonaryVectura

Novartis gains EU and Japan approval for COPD treatments

Novartis gains EU and Japan approval for COPD treatments

24-09-2013

Swiss drug major Novartis has received approval from the European Commission for once-daily Ultibro Breezhaler…

EuropeNovartisPharmaceuticalRegulationRespiratory and PulmonaryUltibro Breezhaler

Further evidence of Ultibro Breezhaler efficacy showcased at ERS meeting

09-09-2013

Swiss drug major Novartis (NOVN: VX) released date data from new analyses for once-daily Ultibro Breezhaler…

NovartisPharmaceuticalResearchRespiratory and PulmonarySeebri BreezhalerUltibro BreezhalerVectura

Two CHMP positives for Novartis

29-07-2013

There was a flow of positive news from the European Medicines Agency on Friday (July 26) for Swiss drug…

Anti-Arthritics/RheumaticsEuropeIlarisNovartisPharmaceuticalRegulationRespiratory and PulmonaryUltibro BreezhalerVectura

UK's NICE approves NHS funding for Novartis' Xolair for all eligible patients

24-07-2013

The UK's drugs watch dog the National Institute for Health and Care Excellence (NICE) has stipulated…

EuropeHealthcareNovartisPharmaceuticalRespiratory and PulmonaryXolair

UK's NICE gives final guidance on Esbriet, Orencia and Xolair

24-04-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today (April 24) published…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEsbrietEuropeInterMuneNovartisOrenciaPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Positive new data on Novartis' once-daily QVA149 in COPD patients

23-04-2013

Results from the 64-week SPARK study published today in Lancet Respiratory Medicine showed that Swiss…

NovartisPharmaceuticalQVA149ResearchRespiratory and Pulmonary

US pulmonologists view refractory asthma patient treatment with biosimilar Xolair by end-2018

10-04-2013

US pulmonologists surveyed by health care advisory firm Decision Resources estimate that only 19% percent…

BiotechnologyBoehringer IngelheimGenentechGenericsMarkets & MarketingNorth AmericaNovartisPfizerRespiratory and PulmonarySpirivaXolair

FDA approves Novartis' TOBI Podhaler and Cangene's first Botulism Antitoxin heptavalent

24-03-2013

The US Food and Drug Administration on Friday approved Swiss drug major Novartis' (NOVN: VX) TOBI Podhaler…

Antibiotics and Infectious diseasesBotulism antitoxinCangeneNorth AmericaNovartisPharmaceuticalRegulationRespiratory and PulmonaryTobi Podhaler

NICE makes U-turn, recommending Novartis' Xolair for children aged six-11 years

07-03-2013

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) has today (March 7)…

EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Genentech Ph III study of omalizumab shows promise in CIU

25-02-2013

Genentech, the US biotech subsidiary of Swiss drug major Roche (ROG: SIX), announced results from a Phase…

BiotechnologyDermatologicalsGenentechNovartisOmalizumabPharmaceuticalRegulationResearchRespiratory and PulmonaryRocheXolair

News briefs from Sanofi, Bayer, GlaxoSmithKline and Novartis

21-12-2012

French drug major Sanofi (Euronext: SAN) has entered into a binding agreement to acquire the animal health…

BayerDosch PharmaceuticalsExjadeFlonaseGlaxoSmithKlineLegalMergers & AcquisitionsMerialNovartisOncologyPharmaceuticalregorafenibRegulationRespiratory and PulmonarySanofi

UK's NICE revokes NHS use of Novartis' Xolair for asthma in children and adults

09-11-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in draft guidance…

EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Novartis/Vectura's QVA149 is filed as a treatment for COPD in Europe; Certican EU approval

26-10-2012

The UK's Vectura Group (LSE: VEC) confirmed that its partner, Swiss drug giant Novartis (NOVN: VX) has…

CerticanEuropeFinancialImmunologicalsNovartisPharmaceuticalQVA149RegulationResearchRespiratory and PulmonaryVectura

Japanese approvals for Eylea, Tresiba, Seebri and Aimix

01-10-2012

There was a flurry of announcements from Japan's Ministry of Health, Labor and Welfare (MHLW) on Friday,…

AimixAsia-PacificBayerCardio-vascularDainippon Sumitomo PharmaDiabetesEyleaNovartisNovo NordiskOphthalmicsPharmaceuticalRegeneronRegulationRespiratory and PulmonarySeebri BreezhalerShionogiTresibaVectura

EU approval for Janssen-Cilag's Dacogen and Novartis/Vectura's Seebri Breezhealer

01-10-2012

The European Commission on Friday approved the marketing authorization for Janssen-Cilag's (a unit of…

Astex PharmaceuticalsDacogenEuropeJanssen-CilagJohnson & JohnsonNovartisOncologyPharmaceuticalRegulationRespiratory and PulmonarySeebri BreezhalerVectura

New data from Novartis on QVA149 and Seebri Breezhaler at ERS

03-09-2012

Further data from the once-daily chronic obstructive pulmonary disease (COPD) clinical trial programs…

NovartisPharmaceuticalQVA149ResearchRespiratory and PulmonarySeebri BreezhalerVectura

Novartis set to file QVA149 filing in EU and Japan by end of year

31-08-2012

Swiss drug major Novartis announced yesterday that the fifth QVA149 (indacaterol maleate/glycopyrronium…

NovartisPharmaceuticalQVA149RegulationResearchRespiratory and PulmonarySeebri BreezhalerVectura

Credit Suisse focus on new drugs for COPD

19-08-2012

New data will be presented at the European Respiratory Society, due to take place in Vienna, Austria,…

aclidiniumAlmirallGlaxoSmithKlineNovartisPharmaceuticalQVA149ResearchRespiratory and PulmonaryTheravanceVecturaZephyr

1 to 25 of 36 results

Back to top